Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 1, 2017Arthritis Research & TherapyOpen Access

Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3

View Full Paper
Ask AI
Bookmark
Share

Authors

KPKarel PavelkaAKAlan KivitzEDEva Dokoupilová

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Pavelka et al. (2017) studied this question.

synapsesocial.com/papers/6aa044222091377acd62867fhttps://doi.org/10.1186/s13075-017-1490-y
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Health-related quality of life in patients with ankylosing spondylitis: a comprehensive review2014 · 100 citations
  2. 2Global prevalence of ankylosing spondylitis2013 · 732 citations
  3. 3Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial2008 · 188 citations
  4. 4Emerging drugs for the treatment of axial and peripheral spondyloarthritis2015 · 48 citations
  5. 5Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept2010 · 50 citations